Drug Approval | June 11, 2026
AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Evonik researchers say they have achieved a significant breakthrough with Ecobiol
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The award places the company in the top 5% globally
Accomplished molecular microbiologist and protein engineer takes charge of CSIR-IMTECH after serving in key scientific and regulatory leadership roles at FSSAI
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
